<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459948</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Host Response Markers of Inflammation and Endothelial Activation Associated with COVID-19 Severity and Mortality: A GeoSentinel Prospective Observational Cohort.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1615</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101615</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The effect of the COVID-19 pandemic on healthcare systems emphasized the need for rapid and effective triage tools to identify patients at risk of severe or fatal infection. Measuring host response markers of inflammation and endothelial activation at clinical presentation may help to inform appropriate triage and care practices in patients with SARS-CoV-2 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled patients with COVID-19 across five GeoSentinel clinical sites (in Italy, Belgium, Canada, and the United States) from September 2020 to December 2021, and analyzed the association of plasma markers, including soluble urokinase-type plasminogen activator receptor (suPAR), soluble tumor necrosis factor receptor-1 (sTREM-1), interleukin-6 (IL-6), interleukin-8 (IL-8), complement component C5a (C5a), von Willebrand factor (VWF-a2), and interleukin-1 receptor antagonist (IL-1Ra), with 28-day (D28) mortality and 7-day (D7) severity (discharged, hospitalized on ward, or died/admitted to the ICU).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 193 patients, 8.9% (16 of 180) died by D28. Higher concentrations of suPAR were associated with increased odds of mortality at D28 and severity at D7 in univariable and multivariable regression models. The biomarkers sTREM-1 and IL-1Ra showed bivariate associations with mortality at D28 and severity at D7. IL-6, VWF, C5a, and IL-8 were not as indicative of progression to severe disease or death. <b>Conclusions</b>: Our findings confirm previous studies' assertions that point-of-care tests for suPAR and sTREM-1 could facilitate the triage of patients with SARS-CoV-2 infection, which may help guide hospital resource allocation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weckman</LastName><ForeName>Andrea M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0002-2200-4008</Identifier><AffiliationInfo><Affiliation>UHN-Toronto General Hospital, University of Toronto, Toronto, ON M5G 1L7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guagliardo</LastName><ForeName>Sarah Anne J</ForeName><Initials>SAJ</Initials><AffiliationInfo><Affiliation>Division of Global Migration and Quarantine, Travelers' Health Branch, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crowley</LastName><ForeName>Valerie M</ForeName><Initials>VM</Initials><Identifier Source="ORCID">0000-0002-2593-1130</Identifier><AffiliationInfo><Affiliation>UHN-Toronto General Hospital, University of Toronto, Toronto, ON M5G 1L7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6017-1181</Identifier><AffiliationInfo><Affiliation>Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piubelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5739-3795</Identifier><AffiliationInfo><Affiliation>Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ursini</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Ierssel</LastName><ForeName>Sabrina H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Antwerp University Hospital (UZA), 2650 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobbi</LastName><ForeName>Federico G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, University of Brescia, 25121 Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emetulu</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>International Society of Travel Medicine, Atlanta, GA 30338, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizwan</LastName><ForeName>Aisha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>International Society of Travel Medicine, Atlanta, GA 30338, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelo</LastName><ForeName>Kristina M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Division of Global Migration and Quarantine, Travelers' Health Branch, Atlanta, GA 30322, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licitra</LastName><ForeName>Carmelo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Orlando Health Travel Medicine and Infectious Disease, Orlando, FL 34761, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Bradley A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Weill Cornell Medical College and the New York Center for Travel and Tropical Medicine, New York, NY 10022, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barkati</LastName><ForeName>Sapha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>J.D. MacLean Centre for Tropical Diseases, McGill University, Montreal, QC H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ngai</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UHN-Toronto General Hospital, University of Toronto, Toronto, ON M5G 1L7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UHN-Toronto General Hospital, University of Toronto, Toronto, ON M5G 1L7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huits</LastName><ForeName>Ralph</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8803-9468</Identifier><AffiliationInfo><Affiliation>Department of Infectious Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar di Valpolicella, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Tropical Medicine Antwerp, 2000 Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamer</LastName><ForeName>Davidson H</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-4700-1495</Identifier><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Medicine, Boston University Chobanian &amp; Avedisian School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center on Emerging Infectious Diseases, Boston University, Boston, MA 02118, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Global Health, Boston University School of Public Health, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libman</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>J.D. MacLean Centre for Tropical Diseases, McGill University, Montreal, QC H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kain</LastName><ForeName>Kevin C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>UHN-Toronto General Hospital, University of Toronto, Toronto, ON M5G 1L7, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, MaRS Centre, TMDT, University of Toronto, 10th Floor 10-351, Toronto, QC M5G 1L7, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1 U01CK000632-01-00</GrantID><Agency>International Society of Travel Medicine</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Public Health Agency of Canada</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055293">Receptors, Urokinase Plasminogen Activator</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055293" MajorTopicYN="Y">Receptors, Urokinase Plasminogen Activator</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">host response</Keyword><Keyword MajorTopicYN="N">morbidity and mortality</Keyword><Keyword MajorTopicYN="N">sTREM-1</Keyword><Keyword MajorTopicYN="N">suPAR</Keyword></KeywordList><CoiStatement>All authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459948</ArticleId><ArticleId IdType="pmc">PMC11512287</ArticleId><ArticleId IdType="doi">10.3390/v16101615</ArticleId><ArticleId IdType="pii">v16101615</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahase E. Coronavirus: COVID-19 has killed more people than SARS and MERS combined, despite lower case fatality rate.  [(accessed on 31 March 2023)];BMJ. 2020 368:m641. doi: 10.1136/bmj.m641. Available online:  https://www.bmj.com/content/368/bmj.m641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m641</ArticleId><ArticleId IdType="pubmed">32071063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L., Van Calster B., Collins G.S., Riley R.D., Heinze G., Schuit E., Bonten M.M.J., Dahly D.L., Damen J.A., Debray T.P.A., et al. Prediction models for diagnosis and prognosis of COVID-19: Systematic review and critical appraisal. BMJ. 2020;369:m1328. doi: 10.1136/bmj.m1328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1328</ArticleId><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikacenic C., Hahn W.O., Price B.L., Harju-Baker S., Katz R., Kain K.C., Himmelfarb J., Liles W.C., Wurfel M.M. Biomarkers of Endothelial Activation Are Associated with Poor Outcome in Critical Illness. PLoS ONE. 2015;10:e0141251. doi: 10.1371/journal.pone.0141251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0141251</ArticleId><ArticleId IdType="pmc">PMC4619633</ArticleId><ArticleId IdType="pubmed">26492036</ArticleId></ArticleIdList></Reference><Reference><Citation>Erdman L.K., Dhabangi A., Musoke C., Conroy A.L., Hawkes M., Higgins S., Rajwans N., Wolofsky K.T., Streiner D.L., Liles W.C., et al. Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: A retrospective case-control study. PLoS ONE. 2011;6:e17440. doi: 10.1371/journal.pone.0017440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0017440</ArticleId><ArticleId IdType="pmc">PMC3045453</ArticleId><ArticleId IdType="pubmed">21364762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19.  [(accessed on 31 March 2023)];J. Med. Virol. 2021 93:250–256. doi: 10.1002/jmv.26232. Available online:  https://pubmed.ncbi.nlm.nih.gov/32592501/</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchié A., Dagna L., Martinod K., Dixon D.L., Van Tassell B.W., Dentali F., Montecucco F., Massberg S., Levi M., et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 2021;21:319–329. doi: 10.1038/s41577-021-00536-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00536-9</ArticleId><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Møller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.  [(accessed on 5 April 2023)];Cell. 2020 181:1036–1045.e9. doi: 10.1016/j.cell.2020.04.026. Available online:  https://pubmed.ncbi.nlm.nih.gov/32416070/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard-Greenblatt M., Boillat-Blanco N., Zhong K., Mbarack Z., Samaka J., Mlaganile T., Kazimoto T., D’acremont V., Kain K.C. Prognostic Accuracy of Soluble Triggering Receptor Expressed on Myeloid Cells (sTREM-1)-based Algorithms in Febrile Adults Presenting to Tanzanian Outpatient Clinics. Clin. Infect. Dis. 2020;70:1304–1312. doi: 10.1093/cid/ciz419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz419</ArticleId><ArticleId IdType="pubmed">31102510</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain S., Sage A.T., del Sorbo L., Cypel M., Martinu T., Juvet S.C., Mariscal A., Wright J., Chao B.T., Shamandy A.A., et al. A biomarker assay to risk-stratify patients with symptoms of respiratory tract infection. Eur. Respir. J. 2022;60:2200459. doi: 10.1183/13993003.00459-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00459-2022</ArticleId><ArticleId IdType="pmc">PMC9753477</ArticleId><ArticleId IdType="pubmed">36104292</ArticleId></ArticleIdList></Reference><Reference><Citation>Leligdowicz A., Conroy A.L., Hawkes M., Richard-Greenblatt M., Zhong K., Opoka R.O., Namasopo S., Bell D., Liles W.C., da Costa B.R., et al. Risk-stratification of febrile African children at risk of sepsis using sTREM-1 as basis for a rapid triage test. Nat. Commun. 2021;12:6832. doi: 10.1038/s41467-021-27215-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27215-6</ArticleId><ArticleId IdType="pmc">PMC8617180</ArticleId><ArticleId IdType="pubmed">34824252</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandna A., Mahajan R., Gautam P., Mwandigha L., Gunasekaran K., Bhusan D., Cheung A.T.L., Day N., Dittrich S., Dondorp A., et al. Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings. Clin. Infect. Dis. 2022;75:E368–E379. doi: 10.1093/cid/ciac224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac224</ArticleId><ArticleId IdType="pmc">PMC9129107</ArticleId><ArticleId IdType="pubmed">35323932</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Singer M., Brahier T., Ngai M., Wright J., Weckman A.M., Erice C., Meuwly J.Y., Hugli O., Kain K.C., Boillat-Blanco N. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department.  [(accessed on 5 April 2023)];J. Allergy Clin. Immunol. 2021 147:99–106.e4. doi: 10.1016/j.jaci.2020.10.001. Available online:  https://pubmed.ncbi.nlm.nih.gov/33045281/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7546666</ArticleId><ArticleId IdType="pubmed">33045281</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuszewski M., Ładny J., Rafique Z., Peacock F., Pruc M., Gasecka A., Szwed P., Jankowski L., Chmielewski J., Panasiuk L., et al. Prediction value of soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients—A systematic review and meta-analysis. Ann. Agric. Environ. Med. 2023;30:142–147. doi: 10.26444/aaem/160084.</Citation><ArticleIdList><ArticleId IdType="doi">10.26444/aaem/160084</ArticleId><ArticleId IdType="pubmed">36999867</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvelli J., Demaria O., Vély F., Batista L., Benmansour N.C., Fares J., Carpentier S., Thibult M.-L., Morel A., Remark R., et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature. 2020;588:146–150. doi: 10.1038/s41586-020-2600-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2600-6</ArticleId><ArticleId IdType="pmc">PMC7116884</ArticleId><ArticleId IdType="pubmed">32726800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Qin L., Zhang P., Li K., Liang L., Sun J., Xu B., Dai Y., Li X., Zhang C., et al. Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. J. Clin. Investig. Insight. 2020;5:e139834. doi: 10.1172/jci.insight.139834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.139834</ArticleId><ArticleId IdType="pmc">PMC7406242</ArticleId><ArticleId IdType="pubmed">32501293</ArticleId></ArticleIdList></Reference><Reference><Citation>Venables W., Ripley B.  Modern Applied Statistics with S. 4th ed. Springer; Berlin/Heidelberg, Germany: 2002.  [(accessed on 28 November 2023)].  Available online:  https://www.stats.ox.ac.uk/pub/MASS4/</Citation></Reference><Reference><Citation>Youden W.J. Index for rating diagnostic tests. Cancer. 1950;3:32–35. doi: 10.1002/1097-0142(1950)3:1&lt;32::AID-CNCR2820030106&gt;3.0.CO;2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(1950)3:1&lt;32::AID-CNCR2820030106&gt;3.0.CO;2-3</ArticleId><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovina N., Akinosoglou K., Eugen-Olsen J., Hayek S., Reiser J., Giamarellos-Bourboulis E.J. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit. Care. 2020;24:187. doi: 10.1186/s13054-020-02897-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02897-4</ArticleId><ArticleId IdType="pmc">PMC7191969</ArticleId><ArticleId IdType="pubmed">32354367</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadello K., Scolletta S., Covajes C., Vincent J.-L. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012;10:2. doi: 10.1186/1741-7015-10-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-10-2</ArticleId><ArticleId IdType="pmc">PMC3275545</ArticleId><ArticleId IdType="pubmed">22221662</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowski S.R., Piironen T., Høyer-Hansen G., Gerstoft J., Pedersen B.K., Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.  [(accessed on 6 April 2023)];J. Acquir. Immune Defic. Syndr. 2005 39:23–31. doi: 10.1097/01.qai.0000157950.02076.a6. Available online:  https://pubmed.ncbi.nlm.nih.gov/15851910/</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.qai.0000157950.02076.a6</ArticleId><ArticleId IdType="pubmed">15851910</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanova V., Ngai M., Weckman A.M., Wright J.K., Zhong K., Richard-Greenblatt M., McDonald C.R., Conroy A.L., Namasopo S., Opoka R.O., et al. Soluble Urokinase-Type Plasminogen Activator Receptor as a Prognostic Marker of Ugandan Children at Risk of Severe and Fatal Malaria. Clin. Infect. Dis. 2021;76:e1079–e1086. doi: 10.1093/cid/ciac457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac457</ArticleId><ArticleId IdType="pubmed">35675322</ArticleId></ArticleIdList></Reference><Reference><Citation>Stauning M.A., Altintas I., Kallemose T., Eugen-Olsen J., Lindstrøm M.B., Rasmussen L.J.H., Gamst-Jensen H., Nehlin J.O., Andersen O., Tingleff J. Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department. J. Emerg. Med. 2021;61:298–313. doi: 10.1016/j.jemermed.2021.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jemermed.2021.03.012</ArticleId><ArticleId IdType="pmc">PMC7997406</ArticleId><ArticleId IdType="pubmed">34092446</ArticleId></ArticleIdList></Reference><Reference><Citation>Altintas I., Eugen-Olsen J., Seppälä S., Tingleff J., Stauning M.A., El Caidi N.O., Elmajdoubi S., Gamst-Jensen H., Lindstrøm M.B., Rasmussen L.J.H., et al. suPAR Cut-Offs for Risk Stratification in Patients With Symptoms of COVID-19. Biomark. Insights. 2021;16:11772719211034685. doi: 10.1177/11772719211034685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/11772719211034685</ArticleId><ArticleId IdType="pmc">PMC8371731</ArticleId><ArticleId IdType="pubmed">34421295</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E., Poulakou G., Milionis H., Metallidis S., Adamis G., Tsiakos K., Fragkou A., Rapti A., Damoulari C., Fantoni M., et al.  Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial.  [(accessed on 1 April 2023)];Nat. Med. 2021 27:1752–1760. doi: 10.1038/s41591-021-01499-z. Available online:  https://pubmed.ncbi.nlm.nih.gov/34480127/</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01499-z</ArticleId><ArticleId IdType="pmc">PMC8516650</ArticleId><ArticleId IdType="pubmed">34480127</ArticleId></ArticleIdList></Reference><Reference><Citation>Klesney-Tait J., Turnbull I.R., Colonna M. The TREM receptor family and signal integration. Nat. Immunol. 2006;7:1266–1273. doi: 10.1038/ni1411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1411</ArticleId><ArticleId IdType="pubmed">17110943</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright S.W., Lovelace-Macon L., Hantrakun V., Rudd K.E., Teparrukkul P., Kosamo S., Liles W.C., Limmathurotsakul D., West T.E. sTREM-1 predicts mortality in hospitalized patients with infection in a tropical, middle-income country. BMC Med. 2020;18:159. doi: 10.1186/s12916-020-01627-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01627-5</ArticleId><ArticleId IdType="pmc">PMC7329452</ArticleId><ArticleId IdType="pubmed">32605575</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020;383:2255–2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali B., Noris M., Lambrecht B.N., Kemper C. The state of complement in COVID-19.  [(accessed on 1 April 2023)];Nat. Rev. Immunol. 2021 22:77–84. doi: 10.1038/s41577-021-00665-1. Available online:  https://www.nature.com/articles/s41577-021-00665-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00665-1</ArticleId><ArticleId IdType="pmc">PMC8672651</ArticleId><ArticleId IdType="pubmed">34912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandna A., Mahajan R., Gautam P., Mwandigha L., Kumar P., Varghese G.M., Koshiaris C., Lubell Y., Burza S. Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study. Open Forum Infect. Dis. 2022;9:ofac526. doi: 10.1093/ofid/ofac526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac526</ArticleId><ArticleId IdType="pmc">PMC9605705</ArticleId><ArticleId IdType="pubmed">36320192</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T., Jurinovic V., Arnreich C., Lipworth B.J., Hellmuth J.C., von Bergwelt-Baildon M., Klein M., Weinberger T. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J. Allergy Clin. Immunol. 2020;146:128–136.e4. doi: 10.1016/j.jaci.2020.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>